Office of the Director, National Institutes of Health; Notice of Meeting, 75573 [2014-29573]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 243 / Thursday, December 18, 2014 / Notices
onto the NIH campus. All visitor vehicles,
including taxis, hotel, and airport shuttles,
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
In order to facilitate public attendance at
the open session of Council in the main
meeting room, Conference Room 6, please
contact Ms. Lisa Kaeser, Program and Public
Liaison Office, NICHD, at 301–496–0536 to
make your reservation, additional seating
will be available in the meeting overflow
rooms, Conference Rooms 7 and 8.
Individuals will also be able to view the
meeting via NIH Videocast. Please go to the
following link for Videocast access
instructions at: https://www.nichd.nih.gov/
about/advisory/nachhd/Pages/virtualmeeting.aspx.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment program, National
Institutes of Health, HHS)
Dated: December 12, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–29570 Filed 12–17–14; 8:45 am]
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Advisory Committee to the Deputy
Director for Intramural Research,
National Institutes of Health.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Advisory Committee
to the Deputy Director for Intramural
Research, National Institutes of Health.
Date: January 9, 2015.
Time: 1:30 p.m. to 3:00 p.m.
Agenda: To discuss the Advisory
Committee to the Deputy Director for
Intramural Research Report
recommendations on the site visit review of
the Office of Animal Care and Use.
Place: National Institutes of Health,
Building 1, Room 160, Tele: 866–556–1098,
Jkt 235001
[FR Doc. 2014–29573 Filed 12–17–14; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
19:23 Dec 17, 2014
Dated: December 12, 2014.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
VerDate Sep<11>2014
Code 48960, 8600 Rockville Pike, Bethesda,
MD 20892, (Telephone Conference Call).
Contact Person: Michael M. Gottesman,
Deputy Director, National Institutes of
Health, Building One, Room 160, Bethesda,
MD 20892, 301–496–1921.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Prospective Grant of Exclusive
License: Multivalent Vaccines for
Rabies Virus and Ebola and Marburg
(Filoviruses)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR 404, that
the National Institutes of Health (NIH),
Department of Health and Human
Services (HHS), is contemplating the
grant of a an exclusive license to
practice the following invention as
embodied in the following patent
applications: E–032–2011/0, Blaney et
al., ‘‘Multivalent Vaccines for Rabies
Virus and Filoviruses’’, U.S. Patent
Application Number 61/439,046, filed
on February 3, 2011, PCT Application
Number PCT/US2012/23575, filed on
February 2, 2012, U.S. Patent
Application Number 13/983,545, filed
on August 2, 2013, European Patent
Application Number 12702953.6, filed
on February 2, 2012, and Canadian
Patent Application Number 2826594,
filed on February 2, 2012, to Exxell BIO,
Inc., having a place of business in
Shoreview, Minnesota, United States of
America. The patent rights in these
SUMMARY:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
75573
inventions have been assigned to the
United States of America and Thomas
Jefferson University.
DATES: Only written comments and/or
application for a license which are
received by the NIH Office of
Technology Transfer on or before
January 20, 2015 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Peter Soukas, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Email:
ps193c@nih.gov; Telephone: (301) 435–
4646; Facsimile: (301) 402–0220.
SUPPLEMENTARY INFORMATION: The
inventors have developed a new
platform based on live or chemically
inactivated (killed) rabies virus (RABV)
virions containing EBOV glycoprotein
(GP) in their envelope. In preclinical
trials, immunization with such
recombinant RABV virions provided
excellent protection in mice against
lethal challenge with the mouse adapted
EBOV and RABV. More specifically, the
inventors have developed a trivalent
filovirus vaccine based on killed rabies
virus virions for use in humans to
confer protection from all medically
relevant filoviruses and RABV. Two
additional vectors containing EBOV
Sudan GP or MARV GP are planned to
be constructed in addition to the
previously developed EBOV Zaire GP
containing vaccine. Live attenuated
vaccines have been developed for use in
at risk nonhuman primate populations
in Africa and inactivated vaccines have
been developed for use in humans. One
recent use contemplated by the
inventors is use of the vaccine
candidates to generate polyclonal sera
against Filoviruses (i.e. Ebola and
Marburg).
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404. The prospective
exclusive license may be granted unless,
within thirty (30) days from the date of
this published notice, NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.
These patent rights are the subject of
a previous Federal Register notice (see
79 FR 18039, Monday, March 31, 2014).
The fields of use may be limited to
production of polyclonal antibodies for
prevention/treatment of Filoviruses in
humans and non-human animals.
E:\FR\FM\18DEN1.SGM
18DEN1
]]>Agencies
[Federal Register Volume 79, Number 243 (Thursday, December 18, 2014)]
[Notices]
[Page 75573]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-29573]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, National Institutes of Health; Notice of
Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Advisory Committee to the Deputy Director for Intramural Research,
National Institutes of Health.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: Advisory Committee to the Deputy Director for
Intramural Research, National Institutes of Health.
Date: January 9, 2015.
Time: 1:30 p.m. to 3:00 p.m.
Agenda: To discuss the Advisory Committee to the Deputy Director
for Intramural Research Report recommendations on the site visit
review of the Office of Animal Care and Use.
Place: National Institutes of Health, Building 1, Room 160,
Tele: 866-556-1098, Code 48960, 8600 Rockville Pike, Bethesda, MD
20892, (Telephone Conference Call).
Contact Person: Michael M. Gottesman, Deputy Director, National
Institutes of Health, Building One, Room 160, Bethesda, MD 20892,
301-496-1921.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance Program Nos. 93.14,
Intramural Research Training Award; 93.22, Clinical Research Loan
Repayment Program for Individuals from Disadvantaged Backgrounds;
93.232, Loan Repayment Program for Research Generally; 93.39,
Academic Research Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187,
Undergraduate Scholarship Program for Individuals from Disadvantaged
Backgrounds, National Institutes of Health, HHS)
Dated: December 12, 2014.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-29573 Filed 12-17-14; 8:45 am]
BILLING CODE 4140-01-P
